Background: Nontypable Haemophilus influenzae (NTHi) is a common bacterial pathogen causing human respiratory tract infections under permissive conditions such as chronic obstructive pulmonary disease. Inhalation of beta2-receptor agonists is a widely used treatment in patients with chronic obstructive pulmonary disease. The aim of this study was to determine the effect of inhalation of beta2 agonists on the host immune response to respiratory tract infection with NTHi.

Methods: Mouse alveolar macrophages were stimulated in vitro with NTHi in the presence or absence of the beta2 receptor agonists salmeterol or salbutamol. In addition, mice received salmeterol or salbutamol by inhalation and were intranasally infected with NTHi. End points were pulmonary inflammation and bacterial loads.

Results: Both salmeterol and salbutamol inhibited NTHi induced tumor necrosis factor-alpha (TNFalpha) release by mouse alveolar macrophages in vitro by a beta receptor dependent mechanism. In line, inhalation of either salmeterol or salbutamol was associated with a reduced early TNFalpha production in lungs of mice infected intranasally with NTHi, an effect that was reversed by concurrent treatment with the beta blocker propranolol. The clearance of NTHi from the lungs was impaired in mice treated with salmeterol or salbutamol, an adverse effect that was prevented by propranolol and independent of the reduction in TNFalpha.

Conclusion: These data suggest that inhalation of salmeterol or salbutamol may negatively influence an effective clearance of NTHi from the airways.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1456968PMC
http://dx.doi.org/10.1186/1465-9921-7-57DOI Listing

Publication Analysis

Top Keywords

salmeterol salbutamol
24
respiratory tract
12
nontypable haemophilus
8
haemophilus influenzae
8
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
mouse alveolar
8
alveolar macrophages
8
inhalation salmeterol
8

Similar Publications

The aim of this study was to analyse the effect of breathing parameters, age, gender and disease status on the lung doses of the two ICS + LABA fixed combination dry powder drugs. Breathing parameters of 113 COPD patients were measured while inhaling through emptied NEXThaler® and Ellipta® inhalers and the corresponding lung doses were calculated. Lung dose of Foster® NEXThaler® was superior to the lung dose of Relvar® Ellipta® in around 85 % of the patients.

View Article and Find Full Text PDF
Article Synopsis
  • G-protein-coupled receptors (GPCRs), especially the β2-adrenergic receptor (β2AR), are vital for drug targeting in treating pulmonary diseases.
  • Our study used coarse-grained molecular dynamics simulations to analyze how salmeterol and salbutamol interact with membranes and the β2AR, revealing that drug molecules often use the receptor surface for better membrane permeability.
  • Findings indicate that enhancing drug interactions with GPCR surfaces could improve therapeutic effectiveness, presenting new avenues for drug development.
View Article and Find Full Text PDF

New ways to repurpose salmeterol in an animal model of fibromyalgia.

Fundam Clin Pharmacol

February 2025

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.

Article Synopsis
  • Fibromyalgia (FM) is a chronic pain syndrome linked to mood issues, sleep problems, and cognitive decline, possibly due to central pain processing dysfunction and neurotransmitter imbalances.* -
  • In a study involving rats, reserpine was used to induce FM-like symptoms, revealing issues like increased pain sensitivity, depressive behaviors, and biochemical disturbances, which were reversed with the administration of salmeterol, a β2 receptor agonist.* -
  • The findings suggest that treatments targeting β2 receptors, like salmeterol, could be an effective approach for managing symptoms associated with fibromyalgia.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!